Medical Research
Stichting Tuberculosis Vaccine Initiative
NETHERLANDS
Total revenue
$1.0M
Total expenses
$962K
Net assets
$130K
Grants received
$636K
3 grants
EIN
980590804
Tax year
2024
Mission
To support integrate translate and prioritise R&D efforts to discover and develop new tuberculosis vaccines that are accessible and affordable for all.
Programs
2 programs
TBVI brings together the efforts of leading universities government institutes biotech and vaccine companies through TB vaccine and biomarker discovery and development projects. TBVI creates an enabling environment through its knowledge-sharing platform including meetings symposia and workshops and through joint collaborative research that stimulates knowledge exchange and creates synergies among R&D partners and other stakeholders in the field.
TBVI supports translation from ideas to tangible products through the advisory services of its Product & Clinical Development Team P&CDT. This team of independent vaccine R&D experts supports TBVIs R&D partners in moving their candidates from discovery to early clinical development. In its strategy TBVI considers the need to: discover and develop safe and effective vaccines for all; prevent infection and transmission of disease; build on the R&D comparative advantage of the TBVI consortium members; make the best use of limited resources and mobilise additional funding.
Financials
FY 2024
Revenue
Expenses
People
8 listed
Meinema
Dir Finance and Adminsitration
$142K
40 hrs/wk
Holleman
Knowledge exchange and networking m
$92K
32 hrs/wk
van RIet
Projectmanagement
$58K
20 hrs/wk
M Tensen
Projectmanagement
$46K
24 hrs/wk
De Lange
General legal counsel
$29K
10 hrs/wk
A Sloots
Projectmanagement
$25K
32 hrs/wk
S Verhoeven
Sr management assistent
$15K
20 hrs/wk
A Middelburg
Sr management assistent
$10K
40 hrs/wk
Grants received
Showing 3 of 3
Funded by
$636K from 1 funder · 3 grants · 2020
$636K · 3 grants · 2020